Slide 1: Corporate Presentation
Corporate Presentation February 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, including, wit
Slide 3: Our Path to Building a Sustainable Hematology Powerhouse
Our Path to Building a Sustainable Hematology Powerhouse Maximize the Value of RYTELO® (imetelstat) - Wholly-Owned, First-in-Class Telomerase Inhibitor o $220M-$240M in expected 2026 RYTELO net product revenue, expected to be driven by strong commercial execution and targeting of appropriate second-
Slide 4: Lower-Risk Myelodysplastic Syndromes: A Serious and Underrecognized Blood Cancer
Lower-Risk Myelodysplastic Syndromes (LR-MDS): A Serious and Underrecognized Blood Cancer LR-MDS is a rare hematologic malignancy, often underrecognized and misunderstood 90% of patients develop 51% of patients will become symptomatic anemia1 transfusion dependent within six months of diagnosis2 Cur
Slide 5: Inspired by the real experiences of people living with blood cancer
Inspired by the real experiences of people living with blood cancer, Geron is advancing science that aims to meaningfully Living with lower-risk myelodysplastic syndrome is a trip you wish you didn't have to take. Some days I can’t even do normal things –grocery improve shopping, tidying up, even wa
Slide 6: RYTELO Approved in the U.S. and EU for Eligible Lower Risk MDS
RYTELO® (imetelstat) Approved in the U.S. and EU for Eligible Lower Risk Myelodysplastic Syndrome* A first-in-class telomerase inhibitor with a unique mechanism of action representing a highly differentiated treatment approved for eligible patients with lower-risk myelodysplastic syndromes (LR-MDS)*
Slide 7: RYTELO Addresses the Core Unmet Needs in LR-MDS
RYTELO® Addresses the Core Unmet Needs in LR-MDS* Higher and durable transfusion independence1 (TI) EFFICACY - 39.8% patients achieved ≥8-week TI vs 15% with placebo1 (P<0.001)1 - Median duration of response of 52 weeks (51.6 weeks from KM analysis)1 Predictable and generally manageable cytopenias,
Slide 8: Durable Transfusion Independence Supported by Phase 3 Results
Durable Transfusion Independence Supported by Phase 3 Results IMerge Phase 3 demonstrated meaningful, sustained clinical benefit for patients with LR-MDS1,2 Randomized, double-blind, placebo-controlled | N=178 (ITT population) | Conducted across 118 sites in 17 countries Median RBC-TI for RYTELO® re
Slide 9: Data Presented at ASH 2025 Suggests Cytopenias Reflect On-Target Activity
Data, Presented at ASH 2025, Suggests Treatment-Emergent Cytopenias Reflect On-Target Activity and are Potentially Associated with TI and Hb Improvement RBC-TI Response to Imetelstat by Maximum Reduction in Platelets or Neutrophils Within the First 2 Cycles of Treatment3,a Key Insights from ASH 2025
Slide 10: RYTELO Performance Metrics
RYTELO Performance Metrics Demand Volume FY 2025 RYTELO Net Growth Revenue RYTELO Annual Net Revenue $220M-$240M3 9% $184M $184M demand increase in Q4 2025 first full year of over Q3 20251 commercial sales 1L and 2L Line Prescribing Patient Starts Accounts $76M ~30% ~1,300 of RYTELO new patients ord
Slide 11: RYTELO Positioned to Lead in Second-Line LR-MDS
RYTELO Positioned to Lead in Second-Line LR-MDS Core Opportunity Second-Line Supported By: ~8,000 1 Favorable FDA Label U.S. Patients1 2 Updated NCCN Guidelines* Addressable Second-line LR-MDS Market 3 Growing Real-World Data & Experience Driving appropriate adoption in second-line where unmet need
Slide 12: Engaging the LR-MDS Community in Surround Sound
Engaging the LR-MDS Community in Surround Sound Digital and Non- Personal Campaigns HCP Commercial Third- Education Party Education Medical Affairs Patient Community Presence at Engagement Hematology Forums Patient Advocacy Disease Awareness
Slide 13: Coordinated Commercial, Medical, and Advocacy Efforts
Coordinated Commercial, Medical, and Advocacy Efforts to Expand Awareness, Confidence, and Appropriate use of RYTELO® Commercial Medical Affairs Patient Advocacy Refined Positioning & Targeting Data & Evidence Expansion Education & Engagement • Targeting engagement with high- • Academic and U.S. foc
Slide 14: A Field Ready Scientific Story
A Field Ready Scientific Story RYTELO® Key Messages Targets telomerase and is thought to induce apoptosis in malignant, disease-causing cells, unlike Unique MOA ESAs, EMAs and HMAs Efficacy 39.8% patients achieved ≥8-week TI vs 15% with placebo (P<0.001)1 Median duration of response of 52 weeks (51.
Slide 15: Opportunities to Expand RYTELO Addressable Market
Opportunities to Expand RYTELO® Addressable Market* Exploring the broad potential of telomerase inhibition across myeloid malignancies Recent/Anticipated Therapeutic Areas Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved Milestones Treatment-emergent Cytopenias LR-MDS Single Agent IMerge and C
Slide 16: Potential to Expand RYTELO Addressable Market with JAK Inhibitor R/R MF Opportunity
Potential to Expand RYTELO Addressable Market with JAK Inhibitor Relapsed Refractory Myelofibrosis Opportunity1 ~12,000 75% of those JAKi U.S. JAKi treated / treated patients fail well-controlled MF patients or discontinue (currently only 3 approved treatments – all JAK inhibitors) treatment JAKi: J
Slide 17: IMbark Phase 2 Trial Evaluated Two Doses to Inform Phase 3 Selection
IMbark Phase 2 Trial Evaluated Two Doses to Inform Selection of the Phase 3 IMpactMF Treatment Dose Randomized Phase 2 study assessing efficacy and safety of imetelstat in R/R myelofibrosis Co-Primary Endpoints: Imetelstat • Symptom and spleen 9.4mg/kg2 IV# every 3 weeks response at week 24 (n= 59)
Slide 18: Overall Survival Outcomes in IMbark Supported Advancement to Phase 3
Overall Survival Outcomes in IMbark Supported Advancement to Phase 3 An overall survival signal was observed at the dose selected for Phase 3 evaluation Secondary Endpoint: Overall Survival1 1.00 Imetelstat 9.4 mg/kg At median follow-up of 41.7 months2: Survival probability 0.75 Imetelstat 4.7 mg/kg
Slide 19: Phase 2 Safety Profile Reinforced Phase 3 Dose Selection
Phase 2 Safety Profile Reinforced Phase 3 Dose Selection Cytopenias were generally manageable and clinical consequences appeared limited IMbark Phase 2 Trial Adverse Events 4.7 mg/kg (n=48) 9.4 mg/kg (n=59) AEs,1 n (%) • Thrombocytopenia and neutropenia All grades Grade ≥3 All grades Grade ≥3 charac
Slide 20: IMpactMF Phase 3 Designed to Confirm Survival Benefit Observed in IMbark
IMpactMF Phase 3 Designed to Confirm Survival Benefit Observed in Phase 2 IMbark First Phase 3 R/R Myelofibrosis Trial with Overall Survival as the Primary Endpoint Recent Projected Milestones: Enrollment Complete; Imetelstat Primary Endpoint: Trial Ongoing* 9.4mg/kg IV# every 3 weeks • Overall Surv
Slide 21: Aligning for Long-Term Growth and Value Creation
Aligning for Long-Term Growth and Value Creation 2026 Net Revenue and Total Operating Expense Guidance RYTELO® Net Product Revenue * Total Operating Expenses $251M $255M $220-$240M1 $230-$240M1 $184M $77M 2024 2025 2026E 2024 2025 2026E 1 2026 Financial Guidance provided by Geron and reiterated on a
Slide 22: Strong IP Position for RYTELO Supports Commercial Opportunity
Strong IP Position for RYTELO® Supports Commercial Opportunity Exclusivity for LR-MDS Expected into 2037 in the U.S. and 2038 in the EU Expected Regulatory Exclusivities and Patent Terms Dec 2030 Mar 2033 ~Aug 2037 PTE Applications filed in U.S. for RYTELO patents Jun Jun 2024 U.S. Data/Market Exclu
Slide 23: Our Path to Building a Sustainable Hematology Powerhouse
Our Path to Building a Sustainable Hematology Powerhouse Maximize the Value of RYTELO® (imetelstat) - Wholly-Owned, First-in-Class Telomerase Inhibitor o $220M-$240M in expected 2026 RYTELO net product revenue, expected to be driven by strong commercial execution and targeting of appropriate second-
Slide 24: Appendix
_ Appendix ———————
Slide 25: NCCN Guidelines Recommend Imetelstat as a Preferred Second-Line Treatment Option
NCCN Guidelines Recommend Imetelstat as a Preferred Second-Line Treatment Option NCCN MDS Guidelines include imetelstat for use for both RS(+) and RS(-) populations in 1st line ESA-ineligible patients and in 2nd line patients regardless of prior therapy RS(+) RS(-) Serum EPO ≤500 mU/mL Serum EPO >50